PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · J Lab Physicians 2021; 13(02): 123-128
DOI: 10.1055/s-0041-1730755
Original Article

Implementation of a Dual-Column Liquid Chromatography-Tandem Mass-Spectrometry Method for the Quantification of Isavuconazole in Clinical Practice

Autoren

  • Dietmar Enko

    1   Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
    2   Institute of Clinical Chemistry and Laboratory Medicine, General Hospital Hochsteiermark, Leoben, Austria

  • Sieglinde Zelzer

    1   Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria

  • Markus Herrmann

    1   Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria

  • Robert Krause

    3   Department of Internal Medicine, Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria

  • Andreas Meinitzer

    1   Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria

Funding None.
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Objectives Therapeutic drug monitoring (TDM) of isavuconazole, which is a novel broad-spectrum antimycoticum against invasive fungal infections, ensures an effective exposure of the drug and minimizes the risk of toxicity. This study is aimed at evaluating the analytical performance of a dual-column liquid chromatography-tandem mass-spectrometry (LC-MS/MS) method for isavuconazole quantification.

Materials and Methods The method was performed on a Voyager TSQ Quantum triple quadrupole instrument equipped with an Ultimate 3000 chromatography system (Thermo Fisher Scientific, San Jose, California, United States). Analytical and preanalytical requirements of the isavuconazole LC-MS/MS method were evaluated. Sample stability measurements were performed at room temperature (RT) and in serum tubes with separator gel.

Results The isavuconazole LC-MS/MS method was linear over the concentration range of 0.2 to 12.8 mg/L. The coefficient of determination (r 2) always exceeded 0.999. Within- and between-run precision ranged between 1.4 to 2.9% and 1.5 to 3.0%, the recovery between 93.9 and 102.7%. At RT, serum samples were stable for 3 days. Isavuconazole serum concentrations were significantly lower after incubation (18 hours) in serum tubes with separator gel at RT.

Conclusion The dual-column isavuconazole LC-MS/MS is a reliable tool for the TDM of isavuconazole. Serum samples are stable for at least 3 days and should be collected in tubes without separator gel.

Keywords

antifungal agents - isavuconazole - liquid chromatography-tandem mass-spectrometry - therapeutic drug monitoring - triazole


Publikationsverlauf

Artikel online veröffentlicht:
15. Juni 2021

© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Cornely OA, Mullane KM, Ostrosky-Zeichner L. et al. Isavuconazole for treatment of rare invasive fungal diseases. Mycoses 2018; 61 (08) 518-533
    CrossrefPubMedSuche in Google Scholar
  • 2 Marty FM, Cornely OA, Mullane KM. et al. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses 2018; 61 (07) 485-497
    CrossrefPubMedSuche in Google Scholar
  • 3 Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol 2012; 8 (06) 759-765
    CrossrefPubMedSuche in Google Scholar
  • 4 Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69 (05) 1162-1176
    CrossrefPubMedSuche in Google Scholar
  • 5 Yoon SJ, Lee K, Oh J, Woo HI, Lee SY. Experience with therapeutic drug monitoring of three antifungal agents using an LC-MS/MS method in routine clinical practice. Clin Biochem 2019; 70: 14-17
    CrossrefPubMedSuche in Google Scholar
  • 6 Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL. Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi. Antimicrob Agents Chemother 2016; 60 (09) 5483-5491
    CrossrefPubMedSuche in Google Scholar
  • 7 Leung KS, Fong BM. LC-MS/MS in the routine clinical laboratory: has its time come. ? Anal Bioanal Chem 2014; 406 (09/10) 2289-2301
    CrossrefPubMedSuche in Google Scholar
  • 8 Enko D, Zelzer S, Fauler G, Herrmann M. Evaluation of a commercial liquid-chromatography high-resolution mass-spectrometry method for the determination of hepcidin-25. Biochem Med (Zagreb) 2019; 29 (02) 020701
    CrossrefPubMedSuche in Google Scholar
  • 9 Smith A, Dowis J, French D. Quantification of serum voriconazole, isavuconazole, and posaconazole by liquid chromatography tandem mass spectrometry (LC-MS/MS). Curr Protoc Toxicol 2018; 76 (01) e47
    CrossrefPubMedSuche in Google Scholar
  • 10 Clinical and Laboratory Standards Institute (CSLI). Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; approved guideline. CSLI Document EP06-A. Wayne, PA: Clinical and Laboratory Standards Institute 2003
  • 11 Clinical and Laboratory Standards Institute (CSLI). Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline. 3rd ed. CSLI Document EP05–A3. Wayne, PA: Clinical and Laboratory Standards Institute 2014
  • 12 U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Bioanalytical Method Validation—Guidance for Industry. Rockeville, MA: Food and Drug Administration; 2018
  • 13 Thompson M, Ellison SLR, Wood R. Harmonized guidelines for single laboratory validation of methods of analysis. Pure Appl Chem 2002; 74: 835-855
    CrossrefSuche in Google Scholar
  • 14 Meinitzer A, Puchinger M, Winklhofer-Roob BM. et al. Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clin Chim Acta 2007; 384 (01/02) 141-148
    CrossrefPubMedSuche in Google Scholar
  • 15 Maertens JA, Raad II, Marr KA. et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016; 387 (10/020) 760-769
    CrossrefPubMedSuche in Google Scholar
  • 16 Mueller SC, Karasch I, Lakner J, Wacke R. Validation of an isavuconazole high-performance liquid chromatography assay in plasma for routine therapeutic drug monitoring applications. Ther Drug Monit 2018; 40 (04) 503-506
    CrossrefPubMedSuche in Google Scholar
  • 17 European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on Bioanalytical Method Validation London: European Medicines Agency 2011
  • 18 Abdel-Hamid ME. Comparative LC-MS and HPLC analyses of selected antiepileptics and beta-blocking drugs. Farmaco 2000; 55 (02) 136-145
    CrossrefPubMedSuche in Google Scholar
  • 19 Müller C, Gehlen D, Blaich C. et al. Reliable and easy-to-use liquid chromatography-tandem mass spectrometry method for simultaneous analysis of fluconazole, isavuconazole, itraconazole, hydroxy-itraconazole, posaconazole, and voriconazole in human plasma and serum. Ther Drug Monit 2017; 39 (05) 505-513
    CrossrefPubMedSuche in Google Scholar
  • 20 Sillén H, Magnell N. Screening ionisation and chromatography conditions for quantitative LC/MS methods. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877 (29) 3581-3588
    CrossrefPubMedSuche in Google Scholar
  • 21 Louw S, Pereira AS, Lynen F, Hanna-Brown M, Sandra P. Serial coupling of reversed-phase and hydrophilic interaction liquid chromatography to broaden the elution window for the analysis of pharmaceutical compounds. J Chromatogr A 2008; 1208 (01/02) 90-94
    CrossrefPubMedSuche in Google Scholar
  • 22 Haggarty J, Oppermann M, Dalby MJ. et al. Serially coupling hydrophobic interaction and reversed-phase chromatography with simultaneous gradients provides greater coverage of the metabolome. Metabolomics 2015; 11 (05) 1465-1470
    CrossrefPubMedSuche in Google Scholar
  • 23 Haggarty J, Burgess KE. Recent advances in liquid and gas chromatography methodology for extending coverage of the metabolome. Curr Opin Biotechnol 2017; 43: 77-85
    CrossrefPubMedSuche in Google Scholar
  • 24 Schuster C, Paal M, Lindner J. et al. Isotope dilution LC-orbitrap-HRMS with automated sample preparation for the simultaneous quantification of 11 antimycotics in human serum. J Pharm Biomed Anal 2019; 166: 398-405
    CrossrefPubMedSuche in Google Scholar
  • 25 McShane AJ, Wang S. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of 5 azole antifungals and 1 active metabolite. Clin Chim Acta 2017; 474: 8-13
    CrossrefPubMedSuche in Google Scholar
  • 26 Quattrocchi F, Karnes HT, Robinson JD, Hendeles L. Effect of serum separator blood collection tubes on drug concentrations. Ther Drug Monit 1983; 5 (03) 359-362
    CrossrefPubMedSuche in Google Scholar
  • 27 Bergqvist Y, Eckerbom S, Funding L. Effect of use of gel-barrier sampling tubes on determination of some antiepileptic drugs in serum. Clin Chem 1984; 30 (03) 465-466
    CrossrefPubMedSuche in Google Scholar
  • 28 Dasgupta A, Dean R, Saldana S, Kinnaman G, McLawhon RW. Absorption of therapeutic drugs by barrier gels in serum separator blood collection tubes. Volume- and time-dependent reduction in total and free drug concentrations. Am J Clin Pathol 1994; 101 (04) 456-461
    CrossrefPubMedSuche in Google Scholar
  • 29 Karppi J, Akerman KK, Parviainen M. Suitability of collection tubes with separator gels for collecting and storing blood samples for therapeutic drug monitoring (TDM). Clin Chem Lab Med 2000; 38 (04) 313-320
    CrossrefPubMedSuche in Google Scholar
  • 30 Schrapp A, Mory C, Duflot T, Pereira T, Imbert L, Lamoureux F. The right blood collection tube for therapeutic drug monitoring and toxicology screening procedures: standard tubes, gel or mechanical separator?. Clin Chim Acta 2019; 488: 196-201
    CrossrefPubMedSuche in Google Scholar